Bone Mineral Density News and Research RSS Feed - Bone Mineral Density News and Research

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015. [More]
Exercise-associated bone loading during adolescence, young adulthood benefits bone density in adulthood

Exercise-associated bone loading during adolescence, young adulthood benefits bone density in adulthood

Men have many reasons to add high-impact and resistance training to their exercise regimens; these reasons include building muscle and shedding fat. Now a University of Missouri researcher has determined another significant benefit to these activities: building bone mass. [More]
Certain genes could lead to stress fracture injuries

Certain genes could lead to stress fracture injuries

In a paper published in The Official Journal of the International Purine Club University of Liverpool researchers have successfully identified how certain genes can contribute towards a person's susceptibility to stress fracture injuries. This research provides a platform for further research into providing a personalised health approach to this common sports injury. [More]
Bone loss linked with ALL therapy occurs during first month of treatment

Bone loss linked with ALL therapy occurs during first month of treatment

Investigators at Children's Hospital Los Angeles have found that significant bone loss - a side effect of chemotherapy for acute lymphoblastic leukemia (ALL) - occurs during the first month of treatment, far earlier than previously assumed. Results of the study will be available online February 4, in advance of publication in the journal Bone. [More]
AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo. [More]
Parathyroid hormone may mediate antihypertensive fracture risk

Parathyroid hormone may mediate antihypertensive fracture risk

Parathyroid hormone levels may be elevated by use of some antihypertensive agents but reduced by others, analysis of the Multi-Ethnic Study of Atherosclerosis suggests. [More]
Active individuals may need to maintain higher vitamin D levels to reduce risk of stress fractures

Active individuals may need to maintain higher vitamin D levels to reduce risk of stress fractures

Vitamin D plays a crucial role in ensuring appropriate bone density. Active individuals who enjoy participating in higher impact activities may need to maintain higher vitamin D levels to reduce their risk of stress fractures, report investigators in The Journal of Foot & Ankle Surgery. [More]
Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. [More]
Cadmium exposure increases risk of osteoporosis and fractures

Cadmium exposure increases risk of osteoporosis and fractures

People who are exposed to higher levels of cadmium have an increased risk of osteoporosis and fractures. Cadmium also affects the kidneys. A doctoral thesis at Sahlgrenska Academy explored this issue in a study of over 900 older men. [More]
Reduced bone mass puts critically ill patients at greater risk for fractures

Reduced bone mass puts critically ill patients at greater risk for fractures

One year after being hospitalized in intensive care, patients have reduced bone mass that puts them at greater risk for fractures, according to a new study published online ahead of print in the American Journal of Respiratory and Critical Care Medicine. [More]
Men with prostate cancer get stronger bones from playing football

Men with prostate cancer get stronger bones from playing football

Men with prostate cancer run the risk of brittle bones as a side-effect of their treatment. But one hour's football training a few times a week counters many of the negative effects of the treatment, according to University of Copenhagen scientists. [More]
Genvoya approved as complete regimen for HIV treatment

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. [More]
Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture. [More]
Low-weight, high-repetition resistance training increases bone density in adults

Low-weight, high-repetition resistance training increases bone density in adults

A new research study published in The Journal of Sports Medicine and Physical Fitness finds that low-weight, high-repetition resistance training increases bone mineral density in adults, challenging assumptions that heavy weight-training is required to build bone mineral density. Participants who completed the study experienced up to 8 percent bone mineral density increases in the legs, pelvis, arms and spine. [More]
Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery. [More]
TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016. [More]
Neighbourhood exposure to fast food outlets associated with lower BMD and BMC in newborns

Neighbourhood exposure to fast food outlets associated with lower BMD and BMC in newborns

New research from the MRC Lifecourse Epidemiology Unit at the University of Southampton in the UK indicates that neighbourhood exposure to fast food outlets is potentially linked to poorer bone development in early childhood. [More]
Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial. [More]
Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Osteoporosis, a disease of progressive bone loss, affects 70 percent of the U.S. population older than age 50: one in two women--and one in five men. These individuals are at risk for fragility fractures, a break that results from a fall, or occurs in the absence of obvious trauma, and most commonly seen in the wrist, the upper arm, the hip, and the spine. [More]
Bisphosphonate drugs linked to greater risk of atypical hip fractures

Bisphosphonate drugs linked to greater risk of atypical hip fractures

The use of bisphosphonates, a group of drugs used to prevent hip breakages in women with osteoporosis, is associated with an increased risk of atypical fractures in this joint, understood as those that occur in less frequent locations. [More]
Advertisement
Advertisement